Teripressin for the treatment of postoperative ascites in cirrhotic liver cancer patients
10.3670.cma.j.issn.1007-631X.2019.08.014
- VernacularTitle:特利加压素治疗肝硬化合并肝癌术后腹腔积液的临床疗效观察
- Author:
Jianping CAI
1
;
Xianghong ZHOU
;
Haibo YU
;
Liancai WANG
;
Deyu LI
Author Information
1. 河南省人民医院肝胆胰腺外科
- Keywords:
Carcinoma,hepatocellular;
Liver Cirrhosis;
Hypertension,portal
- From:
Chinese Journal of General Surgery
2019;34(8):696-699
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical efficacy of teripressin in the treatment of postoperative ascites in patients with cirrhosis and liver cancer.Method 90 patients were divided into experimental group treated with terlipressin on the basis of routine and diuretic treatment,and control group treated with routine and diuretics only.Result There was significant difference in urine volume between the two groups (F =39 401.325,P =0.000).The amount of urine in the experimental group was more than that in the control group.The amount of peritoneal effusion significantly increased after operation (F =265.163,P=0.000),and that in the experimental group was more than that in the control group (F=6.470,P =0.044).The levels of serum creatinine,urea nitrogen,sodium and blood in the two groups were higher than those in the control group (F =6.470,P =0.044).The change of potassium was not obvious,and the difference was not statistically significant (P ＞ 0.05).The average hospitalization time in the experimental group and the control group were (22.2 ± 3.1) d,(26.6 ± 5.1) d respectively,(t =-4.945,P =0.001).Conclusion Terlipressin is effective and safe in the treatment of peritoneal effusion after hepatic cirrhosis combined with hepatocellular carcinoma.
